Nuclear Medicine and Biology
Volume 35, Issue 4 , Pages 393-400, May 2008

[64Cu]diacetyl-bis(N4-methyl-thiosemicarbazone) — a radiotracer for tumor hypoxia

  • Katie A. Wood

      Affiliations

    • Gray Cancer Institute, Northwood, Middlesex
    • Marie Curie Research Wing, Mount Vernon Hospital, Northwood, Middlesex
    • University College Hospital, London
    • Corresponding Author InformationCorresponding author. Marie Curie Research Wing, Mount Vernon Hospital, Northwood, Middlesex, HA6 2RN, UK. Tel.: +44 1923818611x4533; fax: +44 1923844167.
  • ,
  • Wai Lup Wong

      Affiliations

    • Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, Middlesex
  • ,
  • Michele I. Saunders

      Affiliations

    • Gray Cancer Institute, Northwood, Middlesex
    • Marie Curie Research Wing, Mount Vernon Hospital, Northwood, Middlesex
    • University College Hospital, London

Received 29 November 2007; received in revised form 4 February 2008; accepted 6 February 2008. published online 04 April 2008.

Abstract 

Positron emission tomography scanning using the radiotracer-labeled copper (II)-diacetyl-bis(N4-methylthiosemicarbazone) has been proposed as a noninvasive method for evaluating tumor hypoxia. Tumor hypoxia results in a more aggressive tumor phenotype together with resistance to both radiotherapy and chemotherapy. A noninvasive technique for evaluation of tumor hypoxia is not currently available. Validation of this technique would provide clinicians with a tool for determining the most appropriate cancer therapy, prognostic information, and subvolume delineation for the radiotherapy dose escalation to the radioresistant hypoxic regions within a tumor. This review article describes the background to the development of this tracer, its proposed retention mechanism, biodistribution dosimetry and the preclinical and clinical studies to date. It outlines the potential use of this radiotracer for imaging in the field of oncology.

Keywords: Cu-ATSM, PET, Tumor, Hypoxia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0969-8051(08)00034-6

doi:10.1016/j.nucmedbio.2008.02.002

Nuclear Medicine and Biology
Volume 35, Issue 4 , Pages 393-400, May 2008